Stockscreener 앱 받기
16.68
1.58%
0.26
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
Using AI based signals to follow UroGen Pharma Ltd.Long Setup & Fast Exit/Entry Strategy Plans - newser.com
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Cuts Target Price to $36 - 富途牛牛
Bender Robert & Associates Invests $475,000 in Urogen Pharma $URGN - MarketBeat
What technical models suggest about UroGen Pharma Ltd.’s comebackJuly 2025 Market Mood & Momentum Based Trading Ideas - newser.com
Chris Degnan Sells 2,203 Shares of Urogen Pharma (NASDAQ:URGN) Stock - MarketBeat
Understanding UroGen Pharma Ltd.’s price movementEarnings Beat & Safe Swing Trade Setups - newser.com
Is UroGen Pharma Ltd. reversing from oversold territoryJuly 2025 Breakouts & Weekly High Return Opportunities - newser.com
Is UroGen Pharma Ltd. (UR8) stock a momentum leaderJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Urogen Pharma (NASDAQ:URGN) - MarketBeat
UroGen Pharma CFO Degnan sells $37k in shares By Investing.com - Investing.com UK
UroGen Pharma CFO Degnan sells $37k in shares - Investing.com
Is UroGen Pharma Ltd. (UR8) stock worth holding before Fed meeting2025 Geopolitical Influence & Weekly Breakout Watchlists - newser.com
UroGen continues to climb after bladder cancer drug approval - MSN
UroGen Pharma Ltd.'s (NASDAQ:URGN) Price Is Out Of Tune With Revenues - Sahm
Why UroGen Pharma Ltd. (UR8) stock trades below fair value2025 Analyst Calls & Consistent Profit Trade Alerts - newser.com
Is UroGen Pharma Ltd a good long term investmentVolatility Index Analysis & Consistent Triple Returns - earlytimes.in
UroGen Pharma Ltd. stock outlook for YEARPortfolio Value Report & Intraday High Probability Setup Alerts - newser.com
How to recover losses in UroGen Pharma Ltd. stock2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com
Can swing trading help recover from UroGen Pharma Ltd. lossesJobs Report & High Accuracy Swing Entry Alerts - newser.com
NMIBC Market to Experience Notable Growth in Forecast Span - openPR.com
UroGen Pharma (URGN): Maintained Buy Rating by D. Boral Capital | URGN Stock News - GuruFocus
Urogen Pharma (NASDAQ:URGN) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Why UroGen Pharma Ltd. (UR8) stock stays on buy listsMarket Risk Analysis & Scalable Portfolio Growth Methods - newser.com
UroGen’s bladder cancer treatment shows durable response in clinical trials By Investing.com - Investing.com Nigeria
Can machine learning forecast UroGen Pharma Ltd. recoveryAnalyst Downgrade & Weekly Setup with ROI Potential - newser.com
ZUSDURI™ Clinical Review Published in Reviews in Urology™ - GlobeNewswire
Can IL FS Transportation Networks Limited Deliver Margin Expansion Amid InflationEquity Performance Review & Small Investment Portfolio Tips - earlytimes.in
What drives UroGen Pharma Ltd stock priceStock Market Trends & Smart Beta Strategies That Actually Work - earlytimes.in
URGN: UroGen Pharma's ZUSDURI Shows Promising Results for Bladder Cancer - GuruFocus
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer - The Manila Times
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer - GlobeNewswire
Urogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Urogen Pharma (NASDAQ:URGN) Trading Down 5.9%Here's Why - MarketBeat
UroGen Pharma Hits Day High with 15.59% Surge, Outperforming S&P 500 - Markets Mojo
5.74%
자본화:
|
볼륨(24시간):